Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05604781 · ClinicalTrials.gov registry record
Symfony/Synergy IOL Combination Outcomes
A clinical trial, sponsored by Center For Sight.
- Completed
- Registry status
- 41
- Enrollment target
NCT05604781: Completed study, sponsored by Center For Sight.
NCT05604781 is a clinical trial that has completed, run by Center For Sight. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05604781 has completed, sponsored by Center For Sight.
- COMPLETED
- Registry status
- 41 participants
- Enrollment target
Study Summary
Current visual outcomes expectations of cataract patients are similar to those of refractive surgery patients. Their desire is to be spectacle independent for far, intermediate and near vision activities. Some may have already enjoyed freedom from glasses and would like to continue after the cataracts are removed. Different options are available. These options include: mono-vision and presbyopia correcting intraocular lenses (IOL). Presbyopia correcting IOLs include accommodative, multifocals and extended depth of focus (EDOF) IOLs. In a previous study that evaluated the visual outcomes of an EDOF IOL when combined with a multifocal IOL with a +3.25 D add in patients with or without astigmatism undergoing routine cataract surgery showed good outcomes with high patient satisfaction and less dependance on glasses for intermediate and near activities. As technology evolves, new lens models are available in the market. The purpose of this study is to evaluate the latest EDOF and a hybrid multifocal lenses when combined.
Interventions
- DEVICE Symfony & Synergy IOL combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-10-17 |
| Est. Completion | 2023-05-16 |
What the finished NCT05604781 record still lists
NCT05604781 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 41 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Symfony & Synergy IOL combination is the first listed.
NCT05604781 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05604781 about?
NCT05604781 is a clinical study titled "Symfony/Synergy IOL Combination Outcomes". Current visual outcomes expectations of cataract patients are similar to those of refractive surgery patients. Their desire is to be spectacle independent for far, intermediate and near vision activities. Some may have already enjoyed freedom from glasses and would like to continue after the catarac...
What is the current status of trial NCT05604781?
This trial is currently completed. The enrollment target is 41 participants. The study started on 2022-10-17. Estimated completion is 2023-05-16.
What interventions are being tested in trial NCT05604781?
The interventions under investigation include: Symfony & Synergy IOL combination (DEVICE).
Who is sponsoring clinical trial NCT05604781?
This trial is sponsored by Center For Sight, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI